We believe this site might serve you best:

United States

English Continue

This country code will remain if no action is taken to change it.

Don't see your country?
Promega Corporation

Promega Introduces Bioluminescent HDAC Assays that are up to 100-fold More Sensitive...

Promega Introduces Bioluminescent HDAC Assays that are up to 100-fold More Sensitive than Comparable Fluorescence-Based Assays

New Bioluminescent HDAC-Glo™ and SIRT-Glo™ Assays and Screening Systems for Measurement of Deacetylating Activities

MADISON, WISCONSIN (June 28, 2011)

Promega Corporation announced today the launch of highly sensitive bioluminescent assays for the measurement of the relative activities of histone deacetylases (HDAC) for basic research, screening and drug discovery. The new HDAC-Glo™ and SIRT-Glo™ Assays and Screening Systems use a single-reagent-addition, add-mix-measure protocol for easy implementation in bench top to high throughput screening applications, reducing labor and time to results. The systems speed up data acquisition times, and provide 10 to 100-fold higher sensitivity than comparable fluorescence assays. HDACs are key epigenetic regulators of gene transcription and an important new target class of enzymes in drug discovery epigenetics programs aimed at therapeutic areas such as oncology, metabolic diseases, aging and neurological disorders.

The HDAC-Glo™ Assay is broadly useful for class I and II HDAC enzymes in cells, cell extracts, or purified enzyme; the SIRT-Glo™ Assay is broadly useful for NAD+-dependent class III HDAC purified enzymes (Sirtuins or SIRTs). The assays use Promega's patented Ultra-Glo™ recombinant firefly luciferase technology in an add-mix-measure format where the amount of light produced correlates to HDAC enzyme activity. The assays have broad linearity and high sensitivity minimizing the amount of enzyme required and improving the limits of detection for screening applications. The assays are completed in 15-45 minutes and produce a signal half-life greater than three hours, allowing for batch processing of multi-well assay plates. The cell-based HDAC-Glo Assay enables multiplexed viability assays to be performed for applications such as scaffold profiling or target-specific potency evaluation.

For more information please visit: www.promega.com/products/cell-signaling/histone-deacetylase-assays

About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

These pages contain communications on Promega product releases and corporate activities. For additional new product information, see the new products page or the specific product or application area.

For more information about a press release or about Promega in general, contact Promega Corporate Affairs at 1-608-274-4330 or complete this form.

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.

Scientists at Your Service

Scientists at Your Service

We offer a range of services to help you succeed using Promega technologies. From product training to set up of automated systems and development of custom applications—our scientific support goes beyond the basics.

Ask us! We are here to help you.